Neural activity within the brain underlies complex behavior that allows us to interact with our environment. The anterior cingulate cortex (ACC) is believed to mediate appropriate behavioral responses by integrating emotional and cognitive information about external stimuli. If this understanding is correct, then neural activity within the ACC must therefore correlate with behavioral output in response to external experience. The aim of this thesis is to bridge mechanisms identified in vitro with behaviors observed in vivo to determine the neural substrates of ACC mediated behavior. This thesis focuses on glutamatergic receptors that have been established as mediators of excitatory transmission in the ACC. Through a combination of behavioral, pharmacological, biochemical, and electrophysiological methods, this thesis examined how behaviors observed in mouse models of fear learning, chronic pain, and itch correspond with in vitro observations of ACC neuronal activity. Three sets of experiments are presented. The first set investigated cortical LTP-like mechanisms, and assessed whether they could mediate fear learning. These sets of experiments provide in vivo evidence that trace fear learning requires rapid, NMDA receptor dependent, cortical AMPA receptor insertion. The second set of experiments investigated the contribution of forebrain CREB-mediated transcription in behavioral manifestations of chronic pain. These experiments show that forebrain overexpression of CREB is sufficient to enhance mechanical allodynia in animal models of chronic inflammatory or neuropathic pain. Lastly, the final set of experiments show that pruritogen-induced scratching corresponds with enhanced excitatory transmission in the ACC through KA receptor modulation of inhibitory circuitry. Through investigations of multiple behaviors linked to ACC activity, this thesis presents evidence that manifestations of behavior can be observed at the molecular level, and indicates that molecular mechanisms involved in ACC synaptic activity are a good target for translational research into pathological conditions that are related to abnormal ACC activity.

Glutamate is the essential neurotransmitters in pain pathways. The discovery of the vesicular glutamate transporters (VGLUT1-3) has been a fundamental step on the way to describe glutamate-dependent pain pathways. We used the Cre-lox system to construct conditional knockouts with deficient Vglut2 transmission in specific neuronal populations. We generated a Vglut2f/f;Ht-Pa-Cre line to selectively delete Vglut2 from the peripheral nervous system. These Vglut2 deficient mice showed decreased acute nociceptive responses and were less prone to develop an inflammatory state. They did not develop cold allodynia, or heat hyperalgesia and were less hypersensitive to mechanical stimuli in the PSNL chronic pain model. Further analyses of genes with altered expression after nerve injury, revealed candidates for future studies of chronic pain biomarkers. Interestingly, the Vglut2f/f;Ht-Pa-Cre mice developed an elevated itch behavior. To investigate more specific neuronal populations, we analyzed mice lacking Vglut2 in the Nav1.8 population, as inflammatory hyperalgesia, cold pain, and noxious mechanosensation have been shown to depend upon Nav1.8Cre positive sensory neurons. We showed that deleting Vglut2 in Nav1.8Cre positive neurons abolished thermal hyperalgesia in persistent inflammatory models and responses to noxious mechanical stimuli. We also demonstrated that substance P and VGLUT2-dependent glutamatergic transmission are co-required for the development of formalin-induced inflammatory pain and heat hyperalgesia in persistent inflammatory states. Deletion of Vglut2 in a subpopulation of neurons overlapping with the vanilloid receptor (TRPV1) primary afferents in the dorsal root ganglia resulted in a dramatic increase in itch behavior accompanied by a reduced responsiveness to thermal pain. Substance P signaling and VGLUT2-mediated glutamatergic transmission in TRPV1 neurons was co-required for the development of inflammatory pain states. Analyses of an itch phenotype uncovered the pathway within TRPV1 neurons, with VGLUT2 playing a regulatory role and GRPR neurons, which are to plausible converge the itch signal in the spinal cord. These studies confirmed the essential role of VGLUT2-dependent glutamatergic transmission in acute and persistent pain states and identified the roles of specific subpopulations of primary afferent neurons. Additionally, a novel pain and itch transmission pathway in TRPV1/VGLUT2 positive neurons was identified, which could be part of the gate control of pain.

Background: Oxidative stress due to reactive oxygen species (ROS) production is a key factor in the development of heart failure (HF). This study investigated the thioredoxin (Trx) system, which plays a major role in antioxidant defense, in patients suffering from ischemic (ICM) or dilated (DCM) cardiomyopathy. Methods and results: Myocardial tissue from ICM (n = 13) and DCM (n = 13) patients, as well as septal tissue of patients with aortic stenosis but without diagnosed hypertrophic cardiomyopathy or subaortic stenosis (control; n = 12), was analyzed for Trx1, Trx-interacting protein (TXNIP) and E3 ligase ITCH (E3 ubiquitin-protein ligase Itchy homolog) expression. Trx-reductase 1 (TXNRD1) amount and activity, cytosolic cytochrome C content, and apoptosis markers were quantified by means of enzyme-linked immunosorbent assay and multiplexing. Compared with control samples, ITCH and Trx1 expression, TXNRD1 amount and activity were reduced and TXNIP expression was increased in ICM (ITCH: P = .013; Trx1: P = .028; TXNRD1 amount: P = .035; TXNRD1 activity: P = .005; TXNIP: P = .014) but not in DCM samples. A higher level of the downstream apoptosis marker caspase-9 (ICM: 582 ± 262 MFI [P = .995]; DCM: 1251 ± 548 MFI [P = .002], control: 561 ± 214 MFI) was detected in DCM tissue. A higher expression of Bcl-2 was found in DCM (P = .011). Conclusion: The Trx system was impaired in ICM but not in DCM. ITCH appeared to be responsible for the down-regulation of the Trx system. ROS-induced mitochondrial instability appeared to play a role in DCM.

No description available.

This thesis is comprised of two parts. In the first part, we investigated a) the pharmacology of GNTI, a selective kappa opioid receptor antagonist, as a scratch-inducing compound in mice and b) possible mediators and receptors that may be involved in GNTI-induced scratching (itch). We studied if GNTI induces scratching through opioid, histamine, gastrin-releasing peptide (GRP) and/or muscarinic M1 receptors. In the second part, we established similarities and differences between pain and itch using GNTI-induced scratching and formalin-induced nociception models in mice. We found that GNTI (0.03-3 mg/kg, s.c., behind the neck) induces compulsive and vigorous scratching behavior in a dose-dependent manner. A standard submaximal dose (0.3 mg/kg) of GNTI caused animals to scratch 500-600 times in a 30 min observation period. Intrathecal (i.t.) or intraperitoneal (i.p.) administration of GNTI did not elicit scratching behavior. Duration of action of GNTI was 60-70 min and tolerance to the repetitive behavior did not develop. C-fos expressing neurons, in response to GNTI injection, were localized on the lateral side of the superficial layers of the dorsal horn of the cervical spinal cord. Compound 48/80, a chemically different pruritogen, evoked c-fos expression in neurons which are located on the lateral side of the superficial layer of the dorsal horn. These data suggest that both GNTI and compound 48/80 activate a group of sensory neurons located on the lateral side of lamina I and II. Pretreating (at -20 min) and posttreating (at +5 min) mice with the kappa opioid receptor agonist, nalfurafine (0.001-0.03 mg/kg, s.c.), significantly attenuated scratching induced by GNTI (0.3 mg/kg). These effects were not a consequence of behavioral depression. Tolerance did not develop to the anti-scratch activity of nalfurafine. Pretreating mice with nalfurafine (0.02 mg/kg) prevented both GNTI- and compound 48/80-provoked c-fos expression. Our c-fos results suggest that the preclinical antipruritic activity of nalfurafine occurs at the spinal level. Moreover, our results reinforce the need to evaluate nalfurafine as a potentially useful antipruritic in human conditions involving itch. GNTI still elicited excessive scratching in mice lacking mu, delta or kappa opioid receptors, respectively, as well as in mice pretreated with either naloxone or norbinaltorphimine. The H1 receptor antagonist, fexofenadine, or the H4 receptor antagonist, JNJ 10191584, did not attenuate GNTI-induced scratching. Also, pretreating mice with the peptide GRPR antagonist, [D-Phe6]bombesin(6-13) methyl ester, or the non-peptide GRPR antagonist, RC-3095, did not antagonize scratching induced by GNTI. Furthermore, GRPR mRNA levels did not change in response to GNTI injection. Telenzepine, a standard M1 receptor antagonist, had no marked effect against GNTI-elicited scratching, however (unexpectedly) McN-A-343, an M1 receptor agonist, attenuated this behavior in a dose-dependent manner. In the second part of our studies, we found that pretreating mice with lidocaine (i.d., behind the neck) inhibits GNTI-induced scratching and prevents GNTI-provoked c-fos expression in the dorsal horn of the spinal cord. Similarly, lidocaine (i.d., hind leg) inhibits formalin-induced nociception as well as formalin-provoked c-fos expression. While injection (s.c.) of formalin to the face of mice induced only wiping (indicating pain) by forepaws of the injection side, injection (s.c.) of GNTI to the face elicited grooming and scratching (indicating itch). In contrast to formalin, GNTI did not induce c-fos expression in the trigeminal nucleus suggesting that pain and itch sensations are projected differently along the sensory trigeminal pathway. In short, our main results indicate that a) the scratch-inducing activity of GNTI is not mediated by opioid, histamine or GRP receptors; b) kappa opioid receptors are involved, at least in part, in the inhibition of itch sensation and thus, on the basis of our results, nalfurafine holds promise as a potentially useful antipruritic in human conditions involving itch; and c) agonism at M1 receptors inhibits GNTI-induced scratching therefore the M1 receptor may be a key target for antipruritic drug development. / Pharmacology

Chronic itch has a significant impact on quality of life for millions of patients worldwide, on a level comparable to that of chronic pain. Yet, although there are a host of effective drugs available for pain, there are no therapies that specifically target chronic itch. Current experimental approaches to investigate the pathogenesis of chronic pruritus and to test novel therapeutic agents are largely limited to rodent models. However, rodent models display significant dermatological, neurophysiological, and immunological differences from humans with chronic itch. The disadvantages of the current rodent paradigms call for the design of a valid primate model of chronic itch. For four years, we have monitored scratching behavior in a primate colony (n=35) of Cynomolgus macaques (Macaca fascicularis) suffering from idiopathic chronic itch. By comparing molecular and genetic analyses of the primates’ skin to their quantified scratching behavior, we attempted to characterize the underlying mechanisms of chronic itch in this model. Furthermore, the expression of itch-related proteins was examined in both the primate model and in humans with pruritic diseases. The first aim of the study was to characterize the underlying molecular and genetic basis of chronic itch in the primate model. We were able to distinguish specific peripheral targets related to pruritus by correlating the genetic and protein expression results to the primates’ scratching severity. In Aim 1a, RNA-sequencing was performed on skin biopsies from the primates to identify differentially expressed genes in pruritic, lichenified versus non-pruritic, non-lichenified skin. These results were then correlated to the quantified primate scratching behavior. This led to the identification of over 400 genes that were differentially expressed in the skin based on scratching intensity. Many of these differentially expressed transcripts were associated with sensory nerve fibers, keratinocytes, mast cells, or lymphocytes. Selected genes that were overexpressed and correlated to itch intensity were then targeted for immunohistochemical and proteomic analysis in Aim 1b. Immunohistochemical examination of the primate skin biopsies revealed that histamine levels were not elevated in primates that exhibited increased scratching behavior. However, mast cells containing tryptase were significantly increased in the skin of primates with severe scratching as compared to primates with mild scratching. The increased levels of gastrin-releasing peptide and substance P in lichenified skin were also found to be correlated to the primates’ scratching behavior. Of note, transient receptor potential channels V1, V3, and A1 were increased in the epidermis of primate skin, but the numbers of TRPV1+ and TRPA1+ nerve fibers were not significantly different between lichenified and non-lichenified skin. Transcriptome analysis of the opioid receptors and their ligands showed that primates with severe scratching behavior had a significant imbalance between the µ- and κ-opioid receptors and ligands. The µ-opioids had upregulated gene expression, while the κ-opioids were downregulated. In Aim 2, to further characterize this primate model of chronic itch, we compared immunohistochemical results from the primate studies to human findings. Lesional and non-lesional skin biopsies from patients with atopic dermatitis, psoriasis, and cutaneous T-cell lymphoma underwent immunohistochemical analysis in order to reveal the similarities and differences between the primate model and different types of chronic itch in humans. As in the primate model, substance P was found to be increased in the skin of lesional atopic and psoriasis skin. Additionally, similar to primate skin, human atopic and psoriatic skin had high levels of tryptase and its receptor in the epidermis. While IL-31 was only slightly elevated in primates, patients with cutaneous T-cell lymphoma or atopic dermatitis showed a significant correlation between itch severity and IL-31 levels. In conclusion, our primate model displayed expression patterns of many endogenous pruritogens and receptors that were similar to those of humans with atopic dermatitis or psoriasis. While the primate model did not completely mimic these specific pruritic diseases, the overlap of pruritic components suggests a commonality of signaling pathways across several different chronic itch states. The similarity of this primate model to human disease offers the combined advantages of experimental modeling and long-term behavioral follow-up. / Biomedical Sciences

No description available.

Under åren har intensiv forskning pågått för att förbättra maskininlärningsmodellers förmåga att förutse marknadsrörelser. Trots detta har det, under finanshistorien, inträffat flera händelser, såsom "Flash-crash", som har påverkat marknaden och haft dramatiska konsekvenser för prisrörelserna. Därför är det viktigt att undersöka hur modellerna påverkas av manipulativa handlingar på finansmarknaden för att säkerställa deras robusthet och tillförlitlighet i sådana situationer.  För att genomföra detta arbete har processen delats upp i tre steg. Först har en undersökning av tidigare arbeten gjorts för att identifiera de mest robusta modellerna inom området. Detta gjordes genom att träna modellerna på FI-2010 datasetet, som är ett offentligt tillgängligt dataset för högfrekvent handel med aktier på NASDAQ Nordic-börsen. De modeller som undersöktes inkluderade DeepLOB, DeepLOB-Attention, DeepLOB-seq2seq, DTNN och TCN. Det andra steget innefattade att köpa det svenska datasetet från Nasdaq Nordic, vilket tillhandahåller data om svenska aktier Limit Order Book (LOB). De två modellerna som visade bäst resultat i det första steget tränades sedan med detta dataset. Slutligen genomfördes en manipulation på de svenska orderböckerna för att undersöka hur dessa modeller påverkas. Resultatet utgjorde en tydlig bedömning av modellernas robusthet och pålitlighet när det gäller att förutse marknadsrörelser genom en omfattande jämförelse och analys av samtliga tester och deras resultat. Arbetet belyser även hur modellernas resultat påverkas av manipulativa handlingar. Dessutom framgår det hur valet av normaliseringsmetod påverkar modellernas resultat. / Over the years, intensive research has been conducted to enhance the capability of machine learning models to predict market movements. Despite this, during financial history, several events, such as the "Flash-crash," have impacted the market and had dramatic consequences for price movements. Therefore, it is crucial to examine how the models are affected by manipulative actions in the financial market to ensure their robustness and reliability in such situations. To carry out this work, the process has been divided into three steps. Firstly, a review of previous studies was conducted to identify the most robust models in the field. This was achieved by training the models on the FI-2010 dataset, which is a publicly available dataset for high-frequency trading of stocks on the NASDAQ Nordic stock exchange. The examined models included DeepLOB, DeepLOB-Attention, DeepLOB-seq2seq, DTNN, and TCN. The second step involved acquiring the Swedish dataset from Nasdaq Nordic, providing data on Swedish stock Limit Order Books (LOB). The two models that demonstrated the best results in the first step were then trained with this dataset. Finally, a manipulation was performed on the Swedish order books to investigate how these models would be affected. The result constituted a clear assessment of the models' robustness and reliability in predicting market movements through a comprehensive comparison and analysis of all tests and their results. The work also highlights how the models' outcomes are affected by manipulative actions. Furthermore, it becomes evident how the choice of normalization method affects the models' results.

Itch est une ligase de l’ubiquitine impliquée dans la reconnaissance et la dégradation des protéines par le protéasome. Itch contient trois sites phosphorylés par JNK et il a été démontré que la phosphorylation de ces résidus est nécessaire pour que Itch puisse reconnaître et ubiquityler les protéines c-Jun et JunB. Ces sites de phosphorylation se retrouvent dans le domaine PRD responsable des interactions de Itch avec les protéines à domaine SH3. Si la phosphorylation de Itch par JNK est importante pour réguler son activité avec c-Jun et JunB, on connaît peu de choses sur les interactions de Itch avec les protéines à domaine SH3 ainsi que l’implication de la phosphorylation dans leur régulation. Nous avons donc créé des mutants de Itch par mutagenèse dirigée où les sites de phosphorylation étaient remplacés par des alanines (mutant non phosphorylable) et où l’un des trois sites était remplacé par un acide aspartique (mutant constitutivement phosphorylé). Ces mutants sont utilisés dans des tests d’interaction et d’ubiquitylation, dans le but de déterminer l’impact de la phosphorylation de Itch dans la reconnaissance et l’ubiquitylation des protéines SH3. Nos résultats montrent que, contrairement au modèle proposé, la phosphorylation de Itch n’est pas essentielle à l’interaction de Itch avec l’endophiline, mais la phosphorylation de Itch module l’ubiquitylation ainsi que la dégradation de l’endophiline. La régulation de l’interaction de Itch avec ses substrats est donc différente selon le substrat. / Itch is an ubiquitin ligase involved in protein recognition and degradation by the proteasome. Itch has three phosphorylation sites targeted by JNK. These sites overlap a small proline rich domain responsible for Itch binding to SH3 domain proteins. Phosphorylation of Itch is important for Itch interaction with c-Jun and JunB. However, little is known about Itch interaction with SH3 proteins and the impact of phosphorylation on Itch ability to recognize and ubiquitinate SH3 proteins. We created a phosphomimic mutant of Itch and a mutant of Itch that cannot be phosphorylated by JNK. We tested these mutants in interaction and ubiquitination assays to determine their effect on Itch ability to bind and ubiquitinate Endophilin, an SH3 domain protein. Phosphorylation is not a prerequisite for Itch binding to Endophilin but phosphorylation of Itch modulates Itch ability to ubiquitinate Endophilin. Phosphorylation of Itch also modulates Endophilin fate, as phosphomimic Itch induces degradation of Endophilin compared to non-phosphorylated Itch. These results show that phosphorylation regulates Itch activity towards differents substrates in different ways.

Ce projet de recherche explore un nouveau mécanisme de régulation de l’activité du domaine HECT de la ligase Itch. Ce domaine est responsable de la polyubiquitylation des protéines impliquant le plus souvent leur dégradation par le protéasome. Itch est une ligase de l’ubiquitine de la famille CWH contenant un domaine HECT catalytique en C-terminal, quatre domaines WW, et un domaine C2 N-terminal qui est important pour sa localisation cellulaire. Les ligases CWH interagissent par leur domaine WW avec leurs ligands. Un mécanisme proposé pour ces ligases est que la première molécule d’ubiquitine liée au substrat active le domaine HECT de manière à former une chaine d’ubiquitine sur le substrat. Itch a une particularité dans la famille CWH, car elle possède un domaine riche en proline qui lui permet d’interagir avec plusieurs protéines à domaine SH3. Dans cette étude, nous avons déterminé l’effet de l’ubiquitylation initiale des protéines SH3 sur l’activité du domaine HECT de la ligase Itch, et sur la régulation de ces substrats. / The subject of this research is to reveal a new mechanism of regulation of the Itch ubiquitin ligase through its catalytic HECT domain. The HECT domain is in charge of polyubiquitylating proteins, which is often responsible for their degradation by the proteasome. Itch belongs to the CWH subfamily of ubiquitin ligases, characterized by the presence of C-terminal catalytic HECT domain, four WW domains for ligand binding and a N-terminal C2 domain important for the subcellular localization of the ligase. Attachment of a first ubiquitin moïties to the substrates is proposed to stimulate the ligase activity, promoting the creation of a polyubiquitin chain. Itch is the only member of its subfamily that has been shown to interact and promote the ubiquitylation of SH3 domain-containing proteins through a conserved proline-rich region located upstream of the four WW domains. In this work, we have determined the impact of the addition of a single ubiquitin to SH3 domain-containing proteins on the processivity of the ubiquitylation reaction catalysed by Itch and on the regulation of this class of substrates.